Welcome to the Cell Therapy Masterclass Series, a collection of interviews with leading cell therapy experts providing state-of-the-art industry knowledge and likewise key education.
Each short video provides insight into the current state of cell therapy manufacturing, highlighting key successes and challenges for the sector, and exciting advances on the horizon. Our experts also share their valuable thoughts concerning the future of the cell therapy industry.
Mr Aidan Courtney
Aidan Courtney is Chief Executive Officer of Roslin Cells - one of Europe’s leading companies for the production stem cells and the development of new cell therapies. After studying Economics at Cambridge University, Aidan specialised in finance in London before concentrating for the last fifteen years on high technology and science based companies. He has extensive experience of working with leading scientific and technical specialists in many industries and leading multi-discipline teams to develop commercially focussed businesses based on new technologies. Aidan also holds a masters degree in law and is Associate Member of the J Kenyon Mason Institute for Medicine, Life Sciences and Law at the University of Edinburgh.
Dr Paul Kemp
Paul Kemp has been involved in commercial regenerative medicine for over 25 years. He has a successful track record in virtually all aspects of the business from founding biotech companies, raising significant public and private funding in Europe, US and Asia; designing, building and operating GMP facilities in the US and UK; designing and operating clinical trials including extensive interactions with the MHRA, EMA and FDA; operating multi national, multi centre Phase I, II and III studies, and finally, launching marketing and selling cell based products both in the US and UK. He is the inventor on several patents related to multiple regenerative medicine products both in development and on the market and publishes and presents widely in the field. Paul has a BSc in biochemistry from the University College of Wales, a doctorate in the chemical structure of skin from the University of Leeds and carried out post doctorate studies on collagen cross-linking in skin at the University of Manchester.
Dr Mark Lowdell
Mark Lowdell trained as an immunopathologist at the Royal London Hospital and moved to the Royal Free Hospital / UCL in 1994 to set up the immunotherapy programme in malignant haematology. He has specialist knowledge of cellular therapeutics and is the UK representative on the Joint Accreditation Committee ISCT/EBMT (JACIE) which is responsible for setting and co-ordinating standards for cellular therapies across Europe. Mark holds Qualified Person status for the release of investigational somatic cell therapy medicinal products in the EU and is a Designated Individual under a Human Tissue Authority licence for therapeutic cells.
Dr Stephen Ward
Stephen Ward was appointed as Chief Operating Officer of the Cell Therapy Catapult In January 2013. He brings over 17 years of biological medicine research, development, and manufacturing experience to the organisation. Stephen enjoys converting early research ideas into regulatory compliant products for patients and has developed and validated scalable, commercial manufacturing processes for cell based medicinal products, vaccines, and recombinant biologicals using Quality by Design principles. In addition, his recent interests have been in the use of multi-disciplinary commercial/academic programmes (early in the product lifecycle) to predict the effects of manufacturing stress upon cell-based therapies.
Prior to joining the Cell Therapy Catapult, Stephen worked for Stabilitech, Onyvax, and Medeva, as well as with Prof. Wren at Bart's Medical School and Prof. Dougan at Imperial College developing novel bacterial vaccines. Stephen is chair of the BIA's Manufacturing Advisory Committee, actively promoting and supporting UK bio-manufacturing at Government as well as grass root level.
Dr Kim Warren
Kim Warren is Head of Custom Development Services for Cell Therapy at Lonza Walkersville Inc., a division of Lonza AG, headquartered in Basel, Switzerland. Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries, and a contract manufacturer for the rapidly growing area of cell therapy. The Development Services group works closely with clients to scale-up and streamline their processes for GMP manufacture of cells for therapeutic use, and includes tissue acquisition, raw material sourcing, and media and assay development. Prior to that, Kim became Director of Cell Biology R&D at Lonza (then Cambrex) in 1999, when Cambrex acquired the start-up company she had founded and run for 3 years. Kim also spent 10 years as an R&D scientist focused on hematopoiesis at both biotech and pharmaceutical companies. She received her PhD in Physiology from the University of Maryland at College Park, and did her post-doctoral training in Immunology at Uniformed Services University of the Health Sciences, Bethesda (MD, US).